Rhythm Pharmaceuticals announces FDA acceptance of sNDA for setmelanotide

Rhythm Pharmaceuticals (RYTM) announced that the FDA has accepted for filing the company’s supplemental new drug application for setmelanotide seeking approval for the treatment of conditions associated with acquired hypothalamic obesity. The FDA has granted Priority Review of the sNDA and assigned a Prescription Drug User Fee Act goal date of December 20. Additionally, the European Medicines Agency has confirmed validation of the Type II variation submission to the Marketing Authorization Application for setmelanotide for the same indication. The application review began on August 16 by the Committee for Medicinal Products for Human Use, which will issue an opinion to the European Commission regarding potential approval.